From the Guidelines
MNM stands for Multiple Myeloma, a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. This condition is characterized by the presence of cancerous plasma cells in the bone marrow, which can lead to anemia, bone lesions, and renal insufficiency 1. The International Myeloma Working Group (IMWG) has updated the disease definition of MM to include biomarkers in addition to existing requirements of cancer research and biostatistics (CRAB) features, such as hypercalcemia, renal insufficiency, anemia, and presence of bone lesions 1. The diagnosis of MM is based on the presence of one or more of the following biomarkers: 60% or more clonal plasma cells in the bone marrow, involved/uninvolved FLC ratio of 100 or more with the involved FLC being 100 mg/L or more, or MRI with more than one focal lesion (involving bone or bone marrow) 1. Key points to consider in the diagnosis and management of MM include:
- The use of sensitive imaging techniques, such as PET/CT and MRI, to diagnose MM and monitor disease progression 1
- The importance of identifying high-risk smoldering myeloma patients who may benefit from early therapy to prevent end-organ damage 1
- The need for regular follow-up and monitoring of patients with MM to optimize treatment outcomes and improve quality of life 1.
From the Research
Definition of MNM
- MNM stands for β-nicotinamide mononucleotide, a compound that has been studied for its potential to increase nicotinamide adenine dinucleotide (NAD) concentrations and improve healthspan and lifespan 2.
Studies on MNM
- A randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial found that NMN supplementation increases blood NAD concentrations and is safe and well tolerated with oral dosing up to 900 mg NMN daily 2.
- The study also found that clinical efficacy expressed by blood NAD concentration and physical performance reaches highest at a dose of 600 mg daily oral intake 2.
Key Findings
- Blood NAD concentrations were statistically significantly increased among all NMN-treated groups at day 30 and day 60 when compared to both placebo and baseline 2.
- No safety issues were found, and NMN supplementation was well tolerated, with walking distance increase during the six-minute walking test being statistically significantly higher in the 300 mg, 600 mg, and 900 mg groups compared to placebo at both days 30 and 60 2.